Assessment of BMS-986460 Response in Heavily Pretreated mCRPC
A single PSA rise of 19% after reaching nadir does not definitively indicate treatment failure with BMS-986460; continued monitoring with repeat PSA measurement in 4-6 weeks is warranted before concluding resistance has emerged. The patient demonstrates a complex pattern that requires careful interpretation given the investigational nature of this agent and lack of established resistance criteria.
Rationale for Continued Monitoring
PSA Kinetics Analysis
Your patient's PSA trajectory shows:
- Initial substantial rise to 25.38 ng/mL (expected with novel AR-targeted mechanisms)
- Sustained decline over several months to nadir of 13.06 ng/mL (48.6% reduction from peak)
- Single measurement increase to 15.60 ng/mL (19% rise)
This pattern does not yet meet established progression criteria. In mCRPC trials, PSA progression typically requires:
- ≥25% increase AND absolute increase ≥2 ng/mL above nadir
- Confirmed by second measurement ≥3-4 weeks later
Your patient's absolute increase (2.54 ng/mL) meets threshold, but the percentage (19%) falls short, and critically, this is a single unconfirmed measurement.
Clinical Context Considerations
Treatment History Impact:
- 8-9 years of abiraterone represents exceptional duration, suggesting initially hormone-sensitive biology
- Post-Pluvicto progression with "relatively low PSMA uptake" indicates heterogeneous disease with potential non-PSMA-driven clones
- Bone-only disease without visceral involvement suggests less aggressive phenotype 1
BMS-986460 Mechanism: As a ligand-directed AR degrader (distinct from abiraterone's CYP17 inhibition), this agent may exhibit different resistance patterns than conventional ARPIs. The initial PSA flare followed by decline suggests on-target activity. Single PSA fluctuations can occur due to:
- Laboratory variation
- Transient disease flare
- Bone turnover in sclerotic lesions
- Intercurrent illness or medications
Recommended Monitoring Strategy
Immediate Actions (Next 4-6 Weeks)
Repeat PSA measurement in 4 weeks to confirm trend
Assess clinical status:
- New bone pain or skeletal events?
- Performance status changes?
- Any new symptoms suggesting progression?
Review baseline imaging timeline:
- When was last bone scan/CT performed?
- Are restaging scans due per protocol?
Interpretation Algorithm
If next PSA shows:
Continued rise (>25% from nadir, confirmed): Consider radiographic restaging with bone scan ± CT to assess for RECIST/bone scan progression before declaring treatment failure 1
Stabilization or decline: Continue BMS-986460 with ongoing monitoring per protocol
Plateau at this level: Maintain treatment if clinically stable; PSA stabilization can represent disease control in heavily pretreated mCRPC
Treatment Sequencing Context
Current Position in Treatment Algorithm
According to 2025 ASCO guidelines 1, after progression on ARPI + docetaxel + Pluvicto, standard options include:
- Cabazitaxel (if fit for chemotherapy)
- PARP inhibitors (if HRR mutations present—ensure testing completed)
- Second-line ARPI (limited efficacy post-abiraterone)
- Radium-223 (for symptomatic bone disease)
Critical consideration: The 2025 ASCO guideline emphasizes that "sequential use of ARPI agents has typically resulted in lower response rates with the second ARPI" 1. However, BMS-986460's degrader mechanism may circumvent some cross-resistance, though this remains investigational.
Biomarker Testing Priority
If not already completed, urgently obtain:
- HRR gene panel (BRCA1/2, ATM, others): PARP inhibitors show significant survival benefit in BRCA1/2-mutated mCRPC 1, 2
- MSI-H/dMMR status: Pembrolizumab option if positive 1
The 2025 ASCO guideline strongly emphasizes "early biomarker testing is crucial before starting treatment for patients with mCRPC" 1. This should have been done before BMS-986460 but remains critical for future planning.
Resistance Considerations
Mechanisms to Consider
If true progression is confirmed:
- AR splice variants (AR-V7): May confer resistance to AR-targeted therapies 3
- Neuroendocrine differentiation: Consider if PSA rises disproportionately to clinical symptoms
- Clonal evolution: Post-Pluvicto selection pressure may have enriched PSMA-negative, AR-independent clones
Future Treatment Options
If BMS-986460 fails:
Cabazitaxel (preferred if fit): Showed OS benefit (13.6 vs 11.0 months, HR 0.64) over second ARPI in CARD trial 1
PARP inhibitor (if BRCA1/2+): Olaparib showed OS benefit (19.1 vs 14.7 months, HR 0.69) in PROfound trial 2
Clinical trial enrollment: Given exhaustion of standard options
Critical Pitfalls to Avoid
Premature treatment discontinuation: Single PSA rise without confirmation or radiographic correlation may lead to abandoning effective therapy
Ignoring biomarker status: Missing HRR mutations means potentially missing PARP inhibitor opportunity with proven survival benefit
Overlooking clinical-radiographic dissociation: PSA may not correlate with disease burden in heavily pretreated patients, especially post-radiopharmaceutical therapy
Delayed restaging: If PSA rise confirmed, radiographic assessment is mandatory before treatment change—PSA alone insufficient for progression determination in this context
Continue BMS-986460 pending confirmatory PSA and maintain close surveillance with repeat measurement in 4 weeks, ensuring biomarker testing is complete to optimize subsequent treatment selection if progression is ultimately confirmed.